Differential distribution of the DNA-PKcs inhibitor peposertib selectively radiosensitizes patient-derived melanoma brain metastasis xenografts.

Radioresistance of melanoma brain metastases limits the clinical utility of conventionally fractionated brain radiation in this disease, and strategies to improve radiation response could have significant clinical impact. The catalytic subunit of DNA-dependent protein kinase (DNA- PKcs) is critical for repair of radiation-induced DNA damage, and inhibitors of this kinase can have potent effects on radiation sensitivity. In this study, the radiosensitizing effects of the DNA-PKcs inhibitor peposertib were evaluated in patient-derived xenografts (PDXs) of melanoma brain metastases (M12, M15, M27). In clonogenic survival assays, peposertib augmented RT- induced killing of M12 cells at concentrations ≥100 nM, and a minimum of 16 h exposure allowed maximal sensitization. This information was integrated with pharmacokinetic modeling to define an optimal dosing regimen for peposertib of 125 mpk dosed just prior to and seven hours after irradiation. Using this drug dosing regimen in combination with 2.5 Gy x 5 fractions of radiation, significant prolongation in median survival was observed in M12-eGFP (104%; p=0.0015) and M15 (50%; p=0.03), while more limited effects were seen in M27 (16%, p=0.04). These data support the concept of developing peposertib as a radiosensitizer for brain metastases and provide a paradigm for integrating in vitro and pharmacokinetic data to define an optimal radiosensitizing regimen for potent DNA repair inhibitors.